[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][C:11]2([C:17]3[CH:18]=[CH:19][CH:20]=[CH:21][C:16]=3[CH2:15][S:14]2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].C(=O)([O-])[OH:23].[Na+].ClC1C=CC=C(C(OO)=O)C=1>C(Cl)Cl>[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][C:11]2([C:17]3[CH:18]=[CH:19][CH:20]=[CH:21][C:16]=3[CH2:15][S:14]2=[O:23])[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:2])[CH3:3]485 mg (1.59 mmole) of 1'-t-butoxycarbonylspiro[benzo[c]thiophene-1(3H),4'-piperidine] [prepared as described in Preparation 3(b)] were dissolved in 5 ml of anhydrous methylene chloride, and 148 mg (1.76 mmole) of sodium hydrogencarbonate were added, followed by 325 mg (1.88 mmole, content: 85%) of m-chloroperbenzoic acid, whilst ice-cooling. The reaction mixture was stirred whilst ice-cooling, for 30 minutes, after which it was diluted with methylene chloride and then washed, in turn, with water and with a saturated aqueous solution of sodium chloride. The solution was dried over anhydrous sodium sulfate, and then the solvent was removed by distillation under reduced pressure, and the resulting residue was purified by thin-layer chromatography, using a 2:1 by volume mixture of ethyl acetate and hexane as the developing solvent, to give 498 mg (yield 98%) of the title compound as white crystals.